$VTRS · Viatris Inc
Viatris filed an 8-K reporting completion of its acquisition of Pacira BioSciences via tender offer and Section 251(h) merger. The offer for $36.50 per share in cash expired Nov 16, 2026, with 32,929,780 shares (66.46%) validly tendered. Pacira is now a wholly owned subsidiary, and its shares will be delisted from Nasdaq.
- Offer price was $36.50 per share in cash.
- 32,929,780 shares tendered, representing 66.46% of outstanding shares.
- Merger completed without Pacira stockholder vote under DGCL Section 251(h).
- Pacira shares to be delisted from Nasdaq Global Select Market.
- Viatris expects $90M–$100M revenue contribution for remainder of 2026.
VTRS traded at $20.64, up 0.61% since filing, a muted reaction consistent with a previously announced deal closing on schedule.
The closing converts a previously announced tender offer into a completed acquisition, adding a non-opioid pain franchise to Viatris's portfolio.
The deal strengthens Viatris's U.S. innovative medicines business and establishes a non-opioid pain management position.
Viatris may not realize anticipated benefits, synergies, or operating efficiencies from the Pacira acquisition.